Eli Lilly and Company $LLY Shares Acquired by Syverson Strege & Co

Syverson Strege & Co lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 309.4% during the 2nd quarter, Holdings Channel reports. The fund owned 1,789 shares of the company’s stock after buying an additional 1,352 shares during the quarter. Syverson Strege & Co’s holdings in Eli Lilly and Company were worth $1,395,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of LLY. Saxony Capital Management LLC increased its position in Eli Lilly and Company by 1.4% during the second quarter. Saxony Capital Management LLC now owns 2,173 shares of the company’s stock worth $1,694,000 after purchasing an additional 29 shares during the last quarter. Great Lakes Retirement Inc. grew its stake in shares of Eli Lilly and Company by 2.2% in the 2nd quarter. Great Lakes Retirement Inc. now owns 11,322 shares of the company’s stock valued at $8,826,000 after buying an additional 239 shares during the period. AlphaStar Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $8,137,000. Haven Private LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $294,000. Finally, Linscomb Wealth Inc. raised its position in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Linscomb Wealth Inc. now owns 3,269 shares of the company’s stock valued at $2,548,000 after buying an additional 49 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. HSBC raised their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a research report on Friday. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research note on Monday, October 20th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Trading Up 2.2%

Shares of NYSE:LLY opened at $862.96 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company’s 50 day moving average is $780.74 and its two-hundred day moving average is $771.60. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market cap of $816.76 billion, a PE ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.